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Abstract 
Monoacylglycerolacetyltransferase-2 (MGAT2) is a potential target for the treatment of type 
II diabetes. We report here the optimisation of a series of MGAT2 inhibitors with regard to 
their potency and permeability. Improvements in permeability, as measured by increased flux 
in a Caco-2 assay, were achieved through substitution at the 9-position of the core. We 
propose that reduction of the NH hydrogen-bond donor strength was primarily responsible for 
these effects. 
 
Body text 
Monoacylglycerolacetyltransferase-2 (MGAT2) is a member of the family of enzymes that 
catalyses the synthesis of diacylglycerol from monoacylglycerol and fatty acyl CoA.
1
 It is 
located in the endoplasmic reticulum and is highly expressed in the small intestine.
2 
Preclinical studies have shown that MGAT2 deficient mice show resistance to obesity, 
hyperglycaemia, hypercholesterolaemia and hepatic steatosis induced by a high fat diet.
3
 
Increased energy expenditure, even in the absence of a high fat diet, is at least partly 
responsible for these protective effects.
4 
Inhibition of MGAT2 has therefore attracted interest 
as a potential mechanism for treatment of the metabolic syndrome. We have recently reported 
a novel series of MGAT2 inhibitors
5 
and herein report further optimization, primarily focused 
on increasing the membrane permeability of the compounds. 
Membrane permeability is a key consideration in drug discovery, particularly in the in vivo 
absorption of oral drugs and the ability of molecules to access intracellular targets. In general, 
within a chemical series, the permeability decreases with increasing polarity although other 
factors, such as molecular weight, are important.
6
 In recent years, the strategy of keeping 
lipophilicity of drug candidates low has been highlighted as a way of increasing the likelihood 
of achieving soluble compounds that are metabolically stable and avoid potential 
toxicological risks.
7
 One of the consequences of working in low lipophilicity space however,  
is that permeability is more likely to become an issue. 
Systematic methylation of the three hydrogen bond donors present in our series of MGAT2 
inhibitors had been previously examined.
5
 This had resulted in improvements in permeability, 
as assessed in a Caco-2 assay (apical pH =6.5; basolateral pH = 7.4).
8
 This was consistent 
 2 
with a reduction in hydrogen bond donor count, but had led to an unacceptable loss in potency 
for the three molecular matched pairs (Figure 1). Notably, methylation of R4 appeared to have 
the least impact on Caco-2 permeability, with more significant changes being observed at R1 
and R7. In attempts to achieve potent yet permeable compounds, we sought to retain the three 
donors but to modulate their strength by electronic and steric effects through substitution of 
the core aryl ring.
9-12
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Figure 1. Effect of methylation on MGAT2 potency and permeability. 
 
Results from aryl ring substitution of the core are shown in Table 1. In the case of fluoro 
subsitution (2-4), the 6-fluoro resulted in a large drop in potency whereas substitution in the 
8- or 9- positions resulted in less than a two-fold change. In terms of permeability, the 6- and 
8- substitutions resulted in no change, however, 9-substitution, proximal to the amide NH, did 
result in increased permeability. In the case of methoxy substituents (5-7), substitution at the 
6-position was not tolerated with 8-substitution also resulting in a drop in potency. By 
contrast, 9-substitution resulted in an increase in both potency and permeability. Methyl 
substitution (8-10) showed similar SAR in terms of potency, with 6- and 8- substitution 
resulting in lower potencies relative to the un-substituted core. As before, 9-substitution 
resulted in increased potency and an improvement in terms of Ligand Lipophilicity Efficiency 
(LLE)
13
 of +1.3 relative to the un-substituted core. In terms of permeability, for all three 
methyl isomers, the data was very similar to the un-substituted core with no improvement 
observed, even at the 9-position. The pyridyl analogues (11, 12) were also examined. In the 
case of the 8-pyridyl compound the potency was lowered, however, this was accompanied by 
an expected drop in lipophilicity with the value for LLE remaining the same as the phenyl 
matched pair. Here the permeability was measured to be lower as may be expected based on a 
lower lipophilicity compound. The 9-pyridyl compound lost a greater degree of potency than 
would be expected from lipophilicity alone. Interestingly however, it showed a surprising 
increase in permeability relative to the isolipohilic 8-pyridyl isomer and retained similar 
permeability when compared to the more lipophilic aryl core. Our conclusion from these data 
was that modulation of the 9-position offered an opportunity to increase permeability (F, 
OMe, aza-N) and potency (Me, OMe) with methoxy offering an opportunity to do both 
simultaneously.   
 
Table 1. Human MGAT2 potencies, lipophilicity and permeability data for core substitution. 
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 3 
Cpd Substitution MGAT2 IC50
a 
logD7.4 LLE (pIC50-
logD) 
Caco-2 A-B Papp 
(x10
-6
 cm/s) 
1 H 0.911 2.6 3.4 6 
2 6-F 40.4 2.4 2.0 4 
3 8-F 1.49 2.3 3.5 5 
4 9-F 1.95 2.3 3.4 14 
5 6-OMe >100 1.9 - 7 
6 8-OMe 7.61 2.8 2.3 1 
7 9-OMe 0.109 2.6 4.4 12 
8 6-Me 13.6 - - 9 
9 8-Me 13.4 3.0 1.9 7 
10 9-Me 0.052 2.6 4.7 7 
11 8-azaN 10.5 1.6 3.4 1 
12 9-azaN >66 1.8 - 10 
a IC50 value from the human MGAT2 Rapidfire LCMS
®
 assay. 
 
Exploration of the R9 substituent (Table 2) was carried out contemporaneously in a 2,4-
fluoro aniline series which had been previously shown
5
 to be considerably more potent and 
less lipophilic than the 4-trifluoromethyl aniline (contrast matched pair 1 and 13). Methyl 
substitution resulted in an increase in potency although this was less dramatic than seen 
previously (LLE for 10 and 1 = +1.3; LLE for 14 and 13 = +0.5). Cyano substitution 15 
resulted in lower potency and permeability. Trifluoromethyl 16 retained potency and provided 
a dramatic enhancement in permeability. 
Table 2. Human MGAT2 potencies, lipophilicity and permeability data for R9 substitution. 
 
Cpd R9 Substitution MGAT2 IC50
a logD7.4 LLE (pIC50-
logD) 
Caco-2 A-B Papp 
(x10
-6
 cm/s) 
13 H 0.058 1.3 5.9 5 
14 Me 0.016 1.4 6.4 10 
15 CN 0.405 - - 3 
16 CF3 0.030 1.9 5.6 46 
a IC50 value from the human MGAT2 Rapidfire LCMS
®
 assay. 
 
The effect of 9-substitution was also examined in a series with racemic methyl, ethyl (as 
opposed to methyl, methyl) substitution of the bis-amide ring (Table 3). Here the potency 
enhancements seen with 9-substitution were less marked with all substituents examined 
(OMe, Et, Cl) showing similar values of LLE to the un-substituted compound 17. In terms of 
permeability, an enhancement was seen for all 9-substituted compounds, notably so for the 
chloro compound 20. In the case of the methyl substituted compounds, these were synthesised 
in enantiomerically pure form based on the separation of an intermediate by chiral HPLC. 
Isomer 21a (absolute stereochemistry undetermined) was approximately nine-fold more 
potent than enantiomeric 21b resulting in a high value for LLE (6.5). In common with the 
data presented in Tables 1 and 2, methyl substitution offered little to no enhancement of 
permeability. 
Table 3. Human MGAT2 potencies, lipophilicity and permeability data for R9 substitution. 
N
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Cpd R9 Substitution MGAT2 IC50
a logD7.4 LLE (pIC50-
logD) 
Caco-2 A-B Papp 
(x10
-6
 cm/s) 
17
b
 H 0.010 1.7 6.2 8 
18 OMe 0.010 1.8 6.2 22 
19 Et 0.004 2.1 6.3 24 
20 Cl 0.009 1.9 6.1 35 
21a
c 
Me 0.007 1.7 6.5 9 
21b
c
 Me 0.062 1.8 5.4 14 
aIC50 value from the human MGAT2 Rapidfire LCMS
®
 assay. bCompound is the enantiomerically pure (S)-
isomer. 
c
Compounds are enantiomerically pure but the absolute stereochemistry is unknown 
 
With the chloro substituent offering the largest improvements in terms of permeability,
14
 
this was examined in conjunction with other sulphonamide substituents (Table 4).
15
 
Comparison of the 2-fluoro-4-trifluoromethyl sulphonamide pair 22 and 23 with and without 
a 9-chloro substituent shows an approximate three-fold increase in permeability for the chloro 
substituted compound 23. In the case of the 2-methoxy-4-trifluoromethyl sulphonamide 24 an 
increase in lipophilicity was observed together with a further increase in permeability. This 
compound had the highest Caco-2 value (Papp 58 x 10
-6
 cm/s) of any member in the series 
together with high potency (IC50 7 nM). Interestingly, even low lipophilicity compounds 
containing the 2-cyano-4-methyl sulphonamide (25) retained reasonable Caco-2 values (>10 x 
10
-6
 cm/s) despite low logD7.4 values (0.5). As in the case of compound 21, a clear difference 
in potency between the separated enantiomers was observed. 
 
Table 4. Human MGAT2 potencies, lipophilicity and permeability data for combinations 
 
Cpd R9 
Substitution 
 R Aryl 
Substitution 
MGAT2 
IC50
a 
logD7.4 LLE (pIC50-
logD) 
Caco-2 A-B 
Papp (x10
-6
 cm/s) 
22
b
 H 2F,4CF3 0.012 1.9 6.0 9 
23 Cl 2F,4CF3 0.012 2.2 5.7 29 
24 Cl 2OMe,4CF3 0.007 3.0 5.2 58 
25a
c
 Cl 2CN,4Me 0.023 0.4 7.2 14 
25b
c
 Cl 2CN,4Me 0.117 0.6 6.3 11 
aIC50 value from the human MGAT2 Rapidfire LCMS
®
 assay. bCompound is the enantiomerically pure (S)-
isomer. 
c
Compounds are enantiomerically pure but the absolute stereochemistry is unknown. 
 
A graphical overview of the full dataset for this series is shown in Figure 1, of which the 
compounds described in this paper are a subset. Figure 1A shows permeability plotted against 
measured logD7.4 and trellised according to the 9-substitution pattern. A dashed line showing 
the value of Caco-2 A-B Papp = 10 x10
-6
 cm/s has been added to aid visual comparison. For the 
compounds with no substitution at the 9-position, only 2/41 (5%) has a Papp value > 10 x10
-6
 
cm/s. For the 9-methyl set, 12/47 (26%) have a Papp value > 10 x10
-6
 cm/s and when only 
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 5 
compounds with a logD7.4 > 1.5 are considered, this proportion increases to 12/25 (48%). All 
of the 15 compounds with a methoxy, ethyl or chloro substituent show Papp value > 10 x10
-6
 
cm/s, even for those chloro substituted compounds with low lipophilicity (logD7.4 0.5). Figure 
1B shows MGAT2 potency plotted against permeability with a target area (pIC50 >8; Papp > 10 
x10
-6
 cm/s shaded in grey). For the un-substituted series only compound of the set of 54 
satisfy this criterea. For the 9-methyl compounds, 4/44 (10%) are both potent and permeable. 
When the 9-OMe/Et/Cl set are considered, 8/15 (53%) achieve the target, highlighting the 
importance of 9-substitution in achieving potent and permeable compounds in this series. 
 
 
Figure 1. Plots of permeability against logD7.4 (A) and MGAT2 potency against permeability 
(B), grouped by 9-substituent and shaped by 9-substituent. 
In an attempt to understand the influence of the 9-substituent on the electronics of the core, 
the strength of hydrogen-bond donors (logkα) and hydrogen-bond acceptors (logkβ) labelled 
A-D were calculated using quantum mechanics (Gaussian 09 using B3LYP functional and 6-
31G* basis set)
16
 and are summarised in Table 5. The labelling and values for the 9-methyl 
substituted core is shown in the diagram below. Each of the carbonyls has two values 
corresponding to the orbital lobes on the oxygen lone pairs.  These calculations account for 
both through-bond and through-space electronic effects of the 9-substituent. 
 
Table 5. logkα and logkβ values for 9-substituted compounds 
 6 
 
Entry 9-Substituent Logkβ A Logkα B Logkβ C  Logkα D 
1 H 2.12/2.12 0.35 1.37/1.38 0.98 
2 Me 2.22/2.28 0.31 1.44/1.43 0.88 
3 Et 2.25/2.32 0.30 1.48/1.46 0.86 
4 Cl 1.88/1.89 0.57 1.22/1.31 0.71 
5 CF3 1.78.1.74 0.68 1.26/1.15 0.83 
6 CN 1.45/1.54 0.84 1.08/0.92 1.06 
 
The calculated hydrogen-bond donor and acceptor strengths for a range of 9-substituents 
corresponding to the compounds from tables 2 and 3 are shown in table 5.  These compounds 
have fixed aryl substitution (2,4-difluoro) and differ only in the substitution of the bis-amide 
ring (where ethyl or methyl substitution result in equivalent permeability).  Simple bivariate 
statistics were used to elucidate any relationships between Caco-2 Papp and calculated 
hydrogen-bond strength (Caco-2 Papp values have been put on a log-scale so as to be normally 
distributed).  The relationship with the strength of the adjacent hydrogen-bond donor (D) 
clearly shows a strong correlation with log Caco-2 Papp as shown in Figure 2.  The 
probability (P) of this correlation arising by chance is 0.0018, whilst for all other calculated 
hydrogen-bond strengths P ≥ 0.5.  The correlation of permeability with logkα (D) is also 
better than for logD7.4 (P=0.024).  This result helps rationalize the observed permeability: 
Higher permeability is associated with lower hydrogen-bond donor strength (Cl, CF3), and 
low permeability is associated with higher hydrogen-bond donor strength (H, CN).   
 
 
Figure 2.  Bivariate plot of Caco-2 Papp (log scale) and logkα (D) showing a correlation 
between the two.  Open, blue points are from Table 2; closed, green points are from Table 3.  
R
2
 = 0.77; RMSE = 0.46; probability of such a relationship happening by chance is 0.0018. 
 
In order to understand any effects on the solid state of these compounds, small molecule X-
ray crystal structures were obtained of several members of this series. Although there are 
(A) 
(B) 
(C) (D) 
17 
19 20 
21a 
21b 
13 
15 
14 
16 
 7 
differences in symmetry and packing density across the un-substituted compounds (26-28), 
similar packing motifs around a strong H-bonded chain between the amides of the cores with 
a sulphonamide backbone are consistently observed in all three structures (Figure 3). In the 9-
chloro analogue (23), similar amide interactions between the cores are retained, however, it is 
noteworthy that the sulphonamide H-bonding motifs are completely absent in this structure 
(Figure 4).  
 
 
 
 
 
Figure 3. a) Strong H-bonding interactions in 26. These bonds support a chain structure  
down the B axis. b) 26 viewed down the B-axis c) 27 viewed down the b-axis d) 28 viewed 
down the b-axis. 
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Figure 4. a) Strong H-bonding interactions in 23. These bonds support a chain structure down 
the B axis with weaker interactions supporting layering down the a-axis. This is viewed along 
an intersection of the b/c-axis. b) 23 packing down a-axis.   
 
Compounds were synthesized using a modified version of the previously described route
5 
whereby cyclisations were carried out on the amino ester intermediates of type 29 (Scheme 1). 
This circumvented difficulties associated with isolation of the previously employed amino 
acids. The amino esters were synthesized from  amide coupling of 2-amino benzoic acids 30, 
regioselective ring opening of isatoic anhydrides 31 or amide coupling of 2-nitro benzoic 
acids 32 followed by reduction of the nitro group 33. Cyclisation to form the core 34 was 
carried out using acidic conditions and the various substitutions (R6, R8, R9) were generally 
well tolerated with the exception of (R6 = F) which proceeded in low yield (8%). Acetic acid 
was initially used in the cyclisation, however, it was noted that acetylation of the aniline was a 
significant by-product in some cases. This problem was overcome by switching to the more 
sterically hindered pivalic acid resulting in cleaner reaction profiles and higher isolated yields. 
Treatment with chlorosulphonic acid generated the corresponding sulphonyl chlorides 35 with 
excellent regioselectivity for the 7-position regardless of core substitution (R6, R8, R9) in all 
cases (presumably directed by the aniline amide N1). In the case of R9 = CN, this compound 
was made from the fully elaborated sulphonamide with R9 = Br and subjected to palladium 
catalysed cyanation conditions giving compound 15 in good yield.  
The enantiomerically pure compounds 17 and 22 (R9 = H) were obtained by chiral HPLC 
separation of the cyclised core prior to sulphonylation. Treatment with chlorosulphonic acid 
and sulphonamide coupling gave the desired products with the absolute configuration being 
identified as (3S) based on X-ray crystallography. Compounds 21a and 21b (R9 = H) were 
made in a similar fashion although the absolute configuration was not determined. In the case 
of compounds 25a and 25b these were made by chiral separation of racemic 25 and the 
absolute configuration was not determined. 
 9 
 
Scheme 1. General synthetic approaches. Reagents: (a) H2NCR3(Me)COOMe, HATU, 
(
i
Pr)2NEt, DMF, 76-100%; (b) H2NCR3(Me)COOMe, (
i
Pr)2NEt, DMF, 60 °C, 55-70%; (c) 
H2, Pd/C, EtOH, 93-100%; (d) MeCOOH or 
t
BuCOOH, W, 180 - 200 °C, 8-99%; (e) 
ClSO3H, 65 - 90 °C, 32-100%; (f) ArNH2, pyridine, CH2Cl2, 25 - 100 °C, 13-88%; (g) 
Pd2(dba)3, XPhos, Zn, Zn(CN)2, DMA, W, 120 °C, 2 h, 82% 
 
For the aza-analogues it was found that the sulphonylations would not occur on the fully 
elaborated core (presumably due to the electron deficiency of the pyridyl ring) and so these 
were made according to the procedures outlined in Scheme 2. For the 8-aza compound 11, the 
core was constructed from the 2-chloropyridine 36 via amide coupling, Boc deprotection to 
aniline 38 and cyclisation using pivalic acid to the 8-aza core 39. The chloro substituent was 
then displaced with a benzylthiol to give 40 and then oxidized to a sulphonyl chloride and 
quenched with 4-trifluoromethyl aniline to generate sulphonamide 11. For the 9-aza 
compound 12, an alternative approach was utilized whereby the 2-anilinopyridine 41 was 
regioselectively converted to the sulphonyl chloride 42 and then coupled in low yield to form 
the sulphonamide 43. Amide coupling to form anilinoester 44 and cyclisation under pivalic 
acid conditions gave sulphonamide 12. 
 
Scheme 2. Synthesis of aza-analogues 11 & 12. Reagents: (a) H2NC(Me2)COOMe, HATU, 
(
i
Pr)2NEt, DMF, 20 
o
C, 45 min, 90%; (b) TFA, CH2Cl2, 20 
o
C, 3 h, 100%; (c) 
t
BuCOOH, W, 
200 °C, 3 h, 35%; (d) BnSH, 
t
BuOK, DMF, 80 °C, 3 h, 94%; (e) (i) NCS, AcOH, H2O, 20 
o
C, 
10 min; (ii) 4-CF3C6H4NH2, pyridine, 20 
o
C, 3 h, 22%; (f) ClSO3H, 65 °C, 18 h; (g) 4-
CF3C6H4NH2, pyridine, 20 
o
C, 3 d, 9% over 2 steps; (h) H2NC(Me2)COOMe, HATU, 
(
i
Pr)2NEt, DMF, 20 
o
C, 18 h, 29%; (i) 
t
BuCOOH, 200 °C, 28 h, 56%. 
 
As a representative example of this series, compound 20 was profiled further (Table 6). The 
compound showed no significant inhibition against four isoforms of the cytochrome P450 
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 10 
enzymes (CYP1A2, CYP2C9, CYP2D6 and CYP3A4 all IC50 > 30 M) and only weak 
activity against CYP2C19 (IC50 27 M). No inhibition of the hERG ion channel (IC50 >100 
M) was observed. Plasma protein binding showed reasonable free levels (1.7-3.7% free 
across species) in line with the low lipophilicity of the compound (logD7.4 1.9). The measured 
pKa of the sulphonamide NH was 5.9. The aqueous solubility as measured on crystalline 
material was 150 M.  
 
Table 6. Physical properties of compound 20. 
Aqueous 
solubility
a
 
(μM) 
Mouse PPB
b
 
(% free) 
Rat PPB
b
 
(% free) 
Human PPB
b
 
(% free) 
hERG 
IC50 
(μM) 
150 3.7 3.0 1.7 >100 
a
Solubility of compounds in aqueous phosphate buffer at pH 7.4 after 24 hours at 25 
o
C (M). bPPB was 
assessed by equilibrium dialysis in the appropriate species plasma at 37 °C. Free and bound concentrations were 
quantified by LC-UVMS. 
c
Inhibition of hERG channel IC50 (M) in a electrophysiology (IonWorks
TM
) assay. 
The oral pharmacokinetic profile of compound 20 was examined in rat at low dose (3 mg/kg) 
and mouse at high dose (50 mg/kg) with the results are summarised in Table 7. From IV data 
the compound showed moderate clearance in mouse and low clearance in rat together with a 
low volume of distribution in both species. Good bioavailabilities (> 60%) were observed in 
both species.  
 
Table 7. Pharmacokinetic parameters for selected compound 20
a
 
Species 
Clp 
(mL/min/kg) 
Vdss 
(L/kg) 
IV half-life 
(h) 
Oral half-
life (h) 
Bioavailability 
(%) 
Mouse 
Rat 
29 
4.1 
0.5 
0.4 
0.2 
1.3 
1.2 
2.4 
74 
69 
a
Dosed PO at 3 mg/kg (rat) and 50 mg/kg (mouse) in suspension (HPMC/Tween) and IV (1 mg/kg) in 5% 
DMSO: 95% hydroxypropyl β cyclodextrin. Data is mean of two animals in a single experiment. 
 
Conclusion 
In summary we have reported the optimization of a series of MGAT2 inhibitors to give potent 
compounds such as 20 that have favourable physical and pharmacokinetic properties. In 
particular the permeability, as measured by increased flux in a Caco-2 assay, has been 
improved through substitution at the 9-position of the core. This was achieved without 
recourse to increasing the lipophilicity of the compounds but rather through modulation of the 
hydrogen bond donor strength of an amide NH. 
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